ClinicalTrials.gg
RecruitingNCT06795022RHEA-1Updated Oct 14, 2026

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

A Phase 1/2 interventional study of AZD9793 Intravenous (IV) monotherapy and AZD9793 Subcutaneous (SC) monotherapy in Hepatocellular Carcinoma, sponsored by AstraZeneca. Recruiting at 21 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by AstraZeneca · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 14, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
304
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies in Carcinoma, Hepatocellular by AstraZeneca — 7 open to participants now, 16 under way, 5 of them phase 3. Carcinoma, Hepatocellular · AstraZeneca.

Planned enrollment
7th of 17
304 · median 214
Started
2025
with 4 others
Phase 1/2
2 of 25
1 open now
Primary completion
2027-06
later than 8 of 15 live
Registered
20th of 25
by date

Among the 25 studies in Carcinoma, Hepatocellular by AstraZeneca, this one is the 7th largest by planned enrollment of the 17 interventional ones that give a count, is one of 5 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 8 of the 15 other live ones, and was the 20th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

7 of the 25 studies in Carcinoma, Hepatocellular by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies in Carcinoma, Hepatocellular by AstraZeneca, or all of them as a file.
02

Study summary

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.

Read the detailed description

This is a first-time in human, modular Phase I/II, open-label multicentre study of AZD9793 monotherapy administered intravenously (Module 1), or AZD9793 monotherapy administered subcutaneously (Module 2) in patients with advanced or metastatic solid tumours. Each module contains dose-escalation (Part A) and dose-expansion (Part B).

03

Conditions studied

  • Hepatocellular Carcinoma

Keywords

  • Glypican-3
  • GPC3
  • GPC3+ tumours
  • T cell-engaging antibody
  • TCE
  • AZD9793
  • Solid tumours
  • HCC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age ≥ 18 at the time of signing the .
  • GPC3 positive tumour as determined by a central laboratory using an analytically validated IHC assay. Patients who previously received any therapy targeting GPC3 must undergo central laboratory GPC3 testing on tumour tissue collected after completion of the prior GPC3-targeted therapy.
  • Must have at least one according to (RECIST) v1.1
  • Performance status (ECOG PS): 0-1 at screening.
  • Predicted of ≥ 12 weeks.
  • Adequate organ and bone marrow function measured within 28 days prior to first dose as defined by the protocol.
  • use by men or women should be consistent with local regulations, as defined by the protocol.
  • Confirmed advanced recurrent and/or and/or unresectable HCC, which is histopathologically proven based on the criteria established by the World Health Organization.
  • Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C.
  • Score class A.
  • Previous therapy:

Part A: Patients who have received at least one prior line of standard systemic therapy for HCC as per National Comprehensive Cancer Network or other local scientific guidelines and for which a clinical study is the best option for next treatment based on prior response and/or tolerability and/or patient/investigator decision.

Part B: Patients must not have received more than one in the advanced recurrent and/or metastatic setting.

Key Exclusion Criteria:

  • Unresolved toxicity from prior anticancer therapy, including imAEs, of (CTCAE) Grade ≥ 2 except for vitiligo, peripheral neuropathy related to prior anti-cancer therapy, alopecia, endocrine disorders that are controlled with replacement hormone therapy and asymptomatic laboratory abnormalities.
  • Prior to enrolment, participation in another clinical study with an product administered in the last 21 days or 5 half-lives whichever is shorter.
  • CAR-T cell therapy within the last 6 months prior to enrolment on this study.
  • Known allergy or to AZD9793 or any of the of the product as outlined in the IB.
  • Requires chronic therapy (including > 10 mg prednisone/day or equivalent).
  • Received radiation within 14 days prior to first dose of study treatment; palliative radiation to reduce the risk of tumour lysis syndrome (TLS) or CRS/neurotoxicity in participants with bulky disease is permitted.
  • Undergone a major surgical procedure within 14 days prior to first dose of study treatment days to allow adequate healing
  • Experienced unacceptable cytokine release syndrome (CRS) or Immune Effector Cell Associated Neurotoxicity (ICANS) following prior T cell engagers (TCE) or chimeric antigen receptor T (CAR-T) cell therapy.
  • Previous history of hemophagocytic lymphohistiocytosis (HLH) / macrophage activation syndrome (MAS).
  • Active or prior documented or inflammatory disorders within 3 years of start of treatment.
  • Cardiac conditions as defined by the protocol.
  • History of thromboembolic event within the past 3 months prior to the scheduled first dose of study intervention.
  • Central nervous system (CNS) metastases or CNS pathology, as defined by the protocol, within 3 months prior to consent.
  • Infectious disease including active (HIV), and uncontrolled active systemic fungal, bacterial or other infection.
  • Known fibrolamellar HCC, sarcomatoid HCC, or combined hepatocellular malignant cholangiocarcinoma.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
304 participants (estimated)

Study arms

  • Experimental
    Module 1: AZD9793 Intravenous (IV) monotherapy Part A

    Module 1: AZD9793 Intravenous (IV) monotherapy Part A: Dose Escalation

    Drug: AZD9793 Intravenous (IV) monotherapy

  • Experimental
    Module 2: AZD9793 Subcutaneous (SC) monotherapy Part A

    Module 2: AZD9793 Subcutaneous (SC) monotherapy Part A: Dose Escalation

    Drug: AZD9793 Subcutaneous (SC) monotherapy

  • Experimental
    Module 1: AZD9793 Intravenous (IV) monotherapy Part B

    Module 1: AZD9793 Intravenous (IV) monotherapy Part B: Dose Expansion

    Drug: AZD9793 Intravenous (IV) monotherapy

  • Experimental
    Module 2: AZD9793 Subcutaneous (SC) monotherapy Part B

    Module 2: AZD9793 Subcutaneous (SC) monotherapy Part B: Dose Expansion

    Drug: AZD9793 Subcutaneous (SC) monotherapy

Interventions

  • DrugAZD9793 Intravenous (IV) monotherapy

    T cell-engaging antibody that targets GPC3 on tumour cells

  • DrugAZD9793 Subcutaneous (SC) monotherapy

    T cell-engaging antibody that targets GPC3 on tumour cells

06

What researchers measure

Primary outcomes

  1. The number of patients with adverse events

    Number of patients with adverse events by system organ class and preferred term

    Time frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

  2. The number of patients with serious adverse events

    Number of patients with serious adverse events by system organ class and preferred term

    Time frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

  3. The number of patients with adverse events of special interest

    Number of patients with adverse events of special interest by system organ class and preferred term

    Time frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

  4. The number of AEs leading to discontinuation of AZD9793

    Number of AEs that in the opinion of the Investigator or the Sponsor contraindicate further dosing or AEs that meet criteria for discontinuation

    Time frame: From first dose of study drug up to 30 days post last dose and prior to start of subsequent anticancer therapy

  5. The number of patients with dose-limiting toxicity (DLT), as defined in the protocol [Part A Dose Escalation only]

    Number of patients with at least 1 DLT. A DLT is a toxicity as defined in the protocol that occurs from the first dose of study drug up to and including the planned end of the DLT evaluation period that is assessed as unrelated to the disease or disease-related processes under investigation.

    Time frame: From date of first dose of study drug until the end of DLT evaluation period (up to 21, 28 or 35 days depending on dose regimen)

  6. Objective Response Rate (ORR) [Part B Dose Expansion only]

    The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose expansion only.

    Time frame: From first dose of study drug to progressive disease or the last evaluable assessment in the absence of disease progression whichever comes first (up to approximately 2 years)

Secondary outcomes

  1. Objective Response Rate (ORR) [Part A Dose Escalation only]

    The percentage of patients with a confirmed investigator assessed complete or partial response according to response criteria in solid tumours (RECIST 1.1). Dose escalation only.

    Time frame: From first dose of study drug to progressive disease or the last evaluable assessment in the absence of disease progression whichever comes first (up to approximately 2 years)

  2. Best overall response (BOR)

    The best overall radiological visit response the participant achieves per RECIST 1.1 as assessed by the investigator.

    Time frame: From first dose until disease progression or the last evaluable assessment in the absence of progression (up to approximately 2 years)

  3. Duration of response (DoR)

    The time from the date of first response until date of disease progression or death in the absence of disease progression, according to response criteria in solid tumours (RECIST 1.1).

    Time frame: From the first documented objective response (subsequently confirmed) to progressive disease or death in absence of progression (up to approximately 2 years)

  4. Disease Control Rate (DCR) at 12 weeks

    Percentage of patients with confirmed complete or partial response or having stable disease maintained for \>= 11 weeks, at 12 weeks from first dose, according to response criteria in solid tumours (RECIST 1.1).

    Time frame: From first dose of study drug to progressive disease or last evaluable assessment in the absence of disease progression. [Expected to be measured for each patient at 12 weeks]

  5. Durable response rate (DRR)

    Percentage of participants who have a confirmed best overall response of CR or PR with a duration of at least 3 months, 6 months, 9 months, and 12 months.

    Time frame: From first documented objective response (subsequently confirmed) to the date of disease progression or the last evaluable assessment in the absence of progression (up to approximately 2 years)

  6. Time To Response (TTR)

    The time from start of study treatment until the date of first documented objective response, which is subsequently confirmed as assessed by the Investigator per RECIST 1.1.

    Time frame: From start of study treatment until the date of first documented objective response, which is subsequently confirmed as assessed by the Investigator per RECIST 1.1 (up to approximately 2 years)

  7. Percentage change in tumour size

    Percentage change from baseline in target lesion tumour size (sum of longest diameters of target lesions) based on the RECIST v1.1 target lesion measurements as assessed by the Investigator.

    Time frame: From first dose of study drug to the last evaluable assessment

  8. Progression free Survival (PFS)

    The time from the start of study treatment until RECIST 1.1 defined disease progression or death in the absence of disease progression.

    Time frame: From the start of study treatment to progressive disease or death due to any cause (up to approximately 2 years)

  9. Overall Survival (OS) [Dose expansion only]

    The time from the start of study treatment until death due to any cause. Dose expansion only.

    Time frame: From the start of study treatment to death (up to approximately 2 years)

  10. Pharmacokinetics of AZD9793: Maximum serum concentration of the study drug (Cmax)

    Maximum observed serum concentration of the study drug

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (up to approximately 2 years)

  11. Pharmacokinetics of AZD9793: Area Under the concentration-time curve (AUC)

    Area under the serum concentration-time curve

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (up to approximately 2 years)

  12. Pharmacokinetics of AZD9793: Clearance

    A pharmacokinetic measurement of the volume of serum from which the study drug is completely removed per unit time.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (up to approximately 2 years)

  13. Pharmacokinetics of AZD9793: Terminal elimination half-life (t 1/2)

    Terminal elimination half life.

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (up to approximately 2 years)

  14. Immunogenicity of AZD9793

    The number and percentage of participants who develop anti-drug antibodies (ADAs) measured in serum

    Time frame: From the first dose of study intervention, at predefined intervals throughout the study (up to approximately 2 years)

  15. Change in CD8+ Levels

    Percentage change in CD8+ cells measured by IHC in samples taken pre and post treatment

    Time frame: From time of Informed consent, at predefined intervals (including screening, on-treatment or end of treatment) throughout the study (up to approximately 2 years)

07

Study locations

14 of 21 sites recruiting
  • Research Site
    La Jolla, California 92093, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Research Site
    Los Angeles, California 90089, United States
    Recruiting
  • Research Site
    Baltimore, Maryland 21201, United States
    Not yet recruiting
  • Research Site
    Boston, Massachusetts 02114, United States
    Not yet recruiting
  • Research Site
    St Louis, Missouri 63108, United States
    Recruiting
  • Research Site
    Hackensack, New Jersey 07601, United States
    Recruiting
  • Research Site
    Houston, Texas 77030, United States
    Recruiting
  • Research Site
    Chengdu, 610041, China
    Recruiting
  • Research Site
    Guangzhou, 510515, China
    Recruiting
  • Research Site
    Harbin, 150049, China
    Not yet recruiting
  • Research Site
    Shanghai, 201114, China
    Recruiting
  • Research Site
    Pokfulam, 999077, Hong Kong
    Recruiting
  • Research Site
    Shatin, 000000, Hong Kong
    Recruiting
  • Research Site
    Kashiwa, 277-8577, Japan
    Recruiting
  • Research Site
    Yokohama, 241-8515, Japan
    Recruiting
  • Research Site
    Seoul, 06351, South Korea
    Not yet recruiting
  • Research Site
    Seoul, 5505, South Korea
    Recruiting
  • Research Site
    Barcelona, 8035, Spain
    Not yet recruiting
  • Research Site
    Pamplona, 31005, Spain
    Not yet recruiting
  • Research Site
    Taipei, 10002, Taiwan
    Recruiting
  • Research Site
    Taoyuan, 333, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.

Of 72 industry-sponsored phase 1/2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 74. This study's planned 27 months is below that.

Counting every sponsor, half of 136 studies reached it within 53 months; a quarter within 38 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 27, 2025
StartActual
Mar 27, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jun 30, 2028
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
Research Site is now Recruiting
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Research Site is now Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06795022
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 27, 2025
Start date
Mar 27, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

AstraZeneca Clinical Study Information Center
Contact
information.center@astrazeneca.com
1-877-240-9479

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion